The International Committee for Weights and Measures (CIPM) and the US Nuclear Regulatory Commission continue to use the old terminology of quality factors and dose equivalent. The NRC quality factors are independent of linear energy transfer, though not always equal to the ICRP radiation weighting factors.  The NRC's definition of dose equivalent is "the product of the absorbed dose in tissue, quality factor, and all other necessary modifying factors at the location of interest." However, it is apparent from their definition of effective dose equivalent that "all other necessary modifying factors" excludes the tissue weighting factor.  The radiation weighting factors for neutrons are also different between US NRC and the ICRP - see accompanying diagram.
In the pre-marketing controlled clinical studies and their open extensions (2,423 patients with median duration of follow-up of approximately 18 months), % of patients were discontinued due to adverse reactions. The most common adverse reactions that led to treatment discontinuation were: gastrointestinal disorders (%), myalgia (%), and arthralgia (%). The most commonly reported adverse reactions (incidence ≥5%) in Simvastatin controlled clinical trials were: upper respiratory infections (%), headache (%), abdominal pain (%), constipation (%), and nausea (%).
Maple Syrup Urine Disease (MSUD) is a condition that results from improper metabolism of branched-chain amino acids. The aromatic in fenugreek, sotolon, may be used as a diagnostic criteria for MSUD as it exists in the urine of those persons with this metabolic defect and gives the characteristic sweet-scent.  It normally does not appear in healthy person's urine due to no dietary intake, but may appear in those who drink or consume fenugreek, leading to a false diagnosis.  Maternal consumption of sotolon can also transfer into the baby after birth, and cause trans-generational false diagnosis.